$$$$$$$~BIG OTC DD PICKS AND LOW FLOAT MOVERS$$$$$$$

[Crypto__1]

Micro Cap Update on Viaderma Inc ($VDRM)

Micro Cap Update on Viaderma Inc (OTCMKTS: $VDRM)
By Gene Daniel -  May 7, 2017

Viaderma Inc (OTCMKTS:VDRM) has been one of the more active micro caps in recent months. Advertising around MSD (Male Sexual Dysfunction) drugs like Cialis and Viagra dominate sports programming, so the taboo nature of the discussion has subsided over the years. But it is still surprising when you see a stock like Viaderma Inc (OTCMKTS:VDRM) take off, but some digging showed that this falls into the cannabis sector and the share price move is related to the theme of replacing pharma with CBD’s. But this should not surprise those who follow the Erectile Dysfunction (ED) market which is dominated by Cialis and Viagra. But this stock is based on the sales of the topical market for ED, and the growth of medical cannabis.

A look at the price action is a different story, it has been a story of peaks and valleys as investors get their hands around how these shares fit in the cannabis sector.  But look at the yearly chart, and you will see this reflected in the price and volume, and the volatility that comes with new hot sectors. Those who are in the stock know it is up 500% for the year and were as high as +2000% at it’s peak. Volatility in new markets will stay with cannabis for many years so get used to it – it is the toll you pay – to invest and achieve these outsized returns.

Viaderma Inc (OTCMKTS:VDRM) is a specialty pharmaceutical company devoted to bringing new products to market, recently announced that the Company has filed with the (FDA) Food and Drug Administration for a new over the counter or OTC version of its “Premature Ejaculation Drug”. The new “OTC Drug” should have FDA registration approval in approximately 8 weeks and the Company’s name of the new drug will portray prolonged endurance. The Company says it’s recent testing of the drug has proved to be successful in retarding the onset of ejaculation during sexual intercourse.

The market for male sexual dysfunction is dominated by #Viagra and #Cialis both are taken orally for Erectile Dysfunction (ED). The Company’s alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.

Subscribe below and we’ll keep you on top of what’s happening before $VDRM stock makes its next move.



$VDRM 10-Day Chart Below: Premature ejaculation (PE) is the most common male sexual disorder, and it may have a profound negative impact on a man and his partner’s lives. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company.

In the US, topical sprays that treat PE are available OTC. In reported testing these types of products work on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment segment of the sexual dysfunction market has been estimated to be $1.3 Billion dollars for 2017. Also, reported, the market for these types of products could become larger than the tablet or oral (ED) market.

ViaDerma, Inc. (OTCMKTS: $VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

This is an innovative story with a Cannabis twist that replaces synthetics with a natural drug, which has been a positive theme in all small company trades occurring in 2017. It is worth watching how this plays out in this niche market. Shares have been much higher than they are now, but recent bounces may show the company is getting some traction.

We like these natural replacement drugs where a synthetic drug is being replaced by a CBD, and investors like investing in these stocks as they emerge. Investors are beginning to understand, through recent price action, that pharmaceutical companies as we know them are changing forever and for always.


http://oracledispatch.com/2017/05/07/micro-cap-update-viaderma-inc-otcmktsvdrm/ via @Oracle Dispatch




$VDRM Here's Something Viaderma Inc $VDRM Shareholders Should See

By Chris Sandburg / in Biotech, Momentum & Growth, Momentum Stocks, Stocks / on Wednesday, 10 May 2017 10:58 AM / 0

 

https://www.insiderfinancial.com/viaderma-inc-otcmktsvdrm-a-bit-of-due-diligence-on-the-patent-claims/122577/

Viaderma Inc (OTCMKTS:VDRM) took a bit of a hit recently based on the surfacing of some litigation related to the delivery method associated with its lead asset. Over the last few days, however, the company has recovered much of the lost ground, trading up to the tune of around 20% on the Monday open at current prices (midsession on Wednesday) and up close to 10% for the day so far.

With the potential for an FDA green light for its lead registration asset just around the corner, and the company fresh off the back of what was reported as being a successful conference presentation by its CEO relating to the lead target indication – diabetic foot ulcer therapy – it looks as though we could be in for some strength. The litigation dampens sentiment somewhat, however, right now, but a little bit of digging reveals that sentiment need not be impeded by what’s going on.

Here is why.

By way of a bit of background, Viaderma has developed a topical antibacterial formulation of an already FDA registered drug, which it has been able to prove in trials has the potential to treat diabetic foot ulcers successfully in more than 90% of applications. This category of condition is crying out for fresh therapy options right now, and a number of companies have failed in their attempts to bring said options to market just recently. We covered this company not long ago, requesting that management put out some degree of insight (by way of a press release or otherwise) as to how the above-mentioned presentation went. To put it bluntly, we felt that the claims made as to the 90% success rate in this indication were too good to be true, and wanted to see how the scientific community responded to said claims.

Shortly after our coverage, we got exactly what were looking for, with this release.

The product is in final testing for manufacturing, and based on the available evidence, should be a shoo-in for a quick transition toward standard of care therapy in this sector. So what’s holding the company back? Well, as mentioned, there is a claim against the technology that underpins the product.

Specifically, one of the guys who worked on a product (a patent lawyer) with the current CEO and the technology’s initial inventor (a scientist) claims to have ownership rights. If this is the case, it’s potentially terminal for the program. However, it doesn’t take too much digging to prove that the claim is essentially baseless.

Head over to this site.

Insert the following into the field as an application number: 13/729776.

This is the application number for the patent that the guy we’re talking about is trying to challenge – his name is Steven Keough and he’s listed as an inventor on the patent, along with D. Howard Phillips.

Check the status of the patent:

” Abandoned — Failure to Respond to an Office Action”

So first of all, the patent isn’t even a patent – it’s an application.

More important that that, however, it has been abandoned. When a patent application gets abandoned it’s as if nothing has ever been filed. Even if an individual is listed as an inventor on the application, his or her rights to any return based on future commercial application of the technology covered by the initial application are non-existent.

This is all based on a bit of research in a murky area – we aren’t patent lawyers and we don’t work at the USPTO. We may be misinterpreting something (although we’re pretty certain we aren’t), so we’re going to say that it’s important for anyone thinking about acting on our coverage to do a bit of due diligence before doing so.

All said, however, this just looks like a bit of opportunism from Keough.

If that’s the case, then, our bull thesis remains firm, and our attention returns to the science (and the therapeutic application) as near term value inputs.

We will be updating our subscribers as soon as we know more. For the latest updates on VDRM, sign up below!

Sign up for next microcap runner ahead of the crowd.

Submit

Disclosure: We have no position in VDRM and have not been compensated for this article